Although none of these mechanisms have been specifically demonstrated in OSA; these evidences, along with ezrin’s ability to modulate actin dynamics, and promote OSA metastasis in vivo, provide sufficient rationale to target ezrin signalling in OSA. The gene discussed is EZR; the disease is obstructive sleep apnea syndrome.